Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors
Lund, Sweden — 14 December 2023 — Camurus (NASDAQ STO: CAMX) today announces completed enrollment in the randomized, active-controlled Phase 3 SORENTO study evaluating the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with neuroendocrine tumors located in the gastrointestinal tract or pancreas (GEP-NET). “The enrollment of patients in SORENTO has exceeded expectations. Going forward, we will continue to collect data for the primary endpoint assessment of superiority in progression-free survival with CAM2029 compared to current standard medical therapies with